Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Adams, Sylvia; Schmid, P.; S. Rugo, H.; Winer, EP; Loirat, D.; Awada, Ahmad; Cescon, D.W.; Iwata, Hiromitsu; Campone, M.; Nanda, Rita; L. Hui, Rita; Curigliano, Giuseppe; Toppmeyer, D.; O’Shaughnessy, Joyce; Loi, Sherene; Paluch–Shimon, Shani; R. Tan, Antoinette; Card, Deborah; Zhao, Jing; Karantza, V.; Cortés, Javier

doi:10.1093/annonc/mdy517

Public

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Published in Annals of Oncology • Nov 22, 2018

Authors:

Sylvia Adams

P. Schmid

H. S. Rugo

Abstract

BACKGROUND: Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC. PATIENTS AND METHODS: Eligible patients had centr...

Subject

Medicine

Triple-negative breast cancer

Pembrolizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!